DC Vaccination for Post-remission Therapy in AML

Clinical trial NCT02405338 · COMPLETED

Trial details

NCT number: NCT02405338
Sponsor: Medigene AG
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2015-03-01
Primary completion: 2019-11-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.